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ABSTRACT 
BACKGROUND 
Pre-eclampsia is a leading cause of maternal deaths. These deaths primarily result from eclampsia, 
uncontrolled hypertension and/or systemic inflammation. The fullPIERS (Pre-eclampsia Integrated 
Estimate of RiSk) model was developed and validated for women with pre-eclampsia to identify 
their risk of life-ending, -altering, or -threatening complications within 48h of hospital admission 
with pre-eclampsia.  
METHODS  
We assessed the vulnerable organ systems of 2023 women with pre-eclampsia admitted to tertiary 
centres. The outcome of interest was maternal mortality or other serious complications of pre-
eclampsia. Routinely reported and informative variables were included in stepwise backward 
elimination regression model to predict the adverse maternal outcome. Performance was assessed 
using area under the curve (AUC) statistics. Standard bootstrapping techniques were used to assess 
potential overfitting and performance was also assessed in 3 other relevant populations of women 
with a hypertensive disorder of pregnancy (HDP).  
FINDINGS  
Predictors of adverse maternal outcome included gestational age, chest pain/dyspnoea, oxygen 
saturation (SpO2), platelet count, creatinine, and aspartate transaminase. The fullPIERS model AUC 
was 0.88 [95%CI: 0.84, 0.92]. There was no significant overfitting. fullPIERS performed well (AUC 
>0.7) up to 7d after eligibility, and for the other HDP cohorts admitted to various levels and places 
of care.  
INTERPRETATION  
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The fullPIERS model identifies women at increased risk of adverse outcomes up to 7d before 
complications arise and can thereby modify direct patient care (e.g., timing of delivery, place of care), 
improve the design of clinical trials, and inform biomedical investigations related to pre-eclampsia. 
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INTRODUCTION 
Pre-eclampsia is more than proteinuric gestational hypertension alone, is a state of exaggerated 
systemic inflammation, and  remains a leading direct cause of maternal morbidity and mortality 
worldwide (1). Reducing the burden of illness associated with pre-eclampsia (2) will address, in part, 
the aims of Millennium Development Goal 5 (3;4). In high income countries, this excess maternal 
morbidity and mortality relates to both uncontrolled hypertension and the pulmonary and hepatic 
consequences of systemic inflammation (5;6). 
The only cure for pre-eclampsia is delivery. For pre-eclampsia arising remote from term, supportive 
and temporising measures (“expectant management”) are used to improve perinatal outcomes. 
However, the magnitude of the maternal risks associated with expectant management is unclear (1). 
The perinatal benefits of expectant management near term are even less clear (1). Concerns around 
maternal risk have caused experts to hesitate in recommending expectant management either remote 
from, or near to, term (1). At term, maternal benefits derive from a policy of effecting delivery (7). 
The best method of risk assessment in pre-eclampsia pregnancies being managed expectantly or 
during induction of labour remains unclear (8). Currently, assessment is directed by expert opinion-
based guidelines that perform poorly when operationalised (9). A validated tool that allows real-time 
maternal risk stratification is needed to guide care (e.g., expectant management both remote from 
term or during an induction of labour). Previous modelling was unsuccessful in predicting adverse 
outcomes occurring at any time after admission with pre-eclampsia (10). However, being able to 
predict adverse maternal outcomes within a time frame that would inform and guide clinical care 
(e.g., 48 hours - 7 days) would optimise both the management of women admitted with pre-
eclampsia and resource utilisation. 
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Standardising antenatal and postnatal assessment and surveillance of pre-eclampsia with protocols 
that recognise the systemic inflammatory model of pre-eclampsia (1) has been associated with 
reduced maternal morbidity (11). Using this standardised approach, we have developed and validated 
a pre-eclampsia outcome prediction model, the fullPIERS (Pre-eclampsia Integrated Estimate of 
RiSk) model. fullPIERS is designed for use in well-resourced settings. 
 
METHODS 
fullPIERS was developed and internally validated in a prospective, multicentre study of women who 
fulfilled a research definition of pre-eclampsia, and who were admitted to participating academic 
tertiary obstetric centres in Canada, New Zealand, Australia, and the United Kingdom (Appendix). 
All centres had a general policy of expectant management remote from term to maximise temporal 
exposure of the cohort to the natural history of the condition. 
PIERS was conducted as either a continuous quality improvement (n=4 sites) or a consented 
research (n=4 sites initially, eventually only one) project depending on local ethics committee 
requirements. Inpatient women with either suspected or confirmed pre-eclampsia received care that 
included predetermined guidelines for initial assessment and ongoing surveillance (for details see 
(11;12)). 
Women were included if admitted with pre-eclampsia, or having developed pre-eclampsia following 
admission. Pre-eclampsia was defined as: i) blood pressure (BP) ≥140/90mmHg (at least one 
component, twice, ≥4 hours apart, after 20 weeks) and either proteinuria (of ≥2+ by dipstick, 
≥0.3g/d by 24 hour collection, or ≥30mg/mmol by urinary protein:creatinine ratio) or 
hyperuricaemia (greater than local upper limit of local non-pregnancy normal range) (5), ii) HELLP 
syndrome even in the absence of hypertension or proteinuria (13), or iii) superimposed pre-
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eclampsia (rapidly increasing requirements for antihypertensives, systolic BP (sBP) >170mmHg or 
diastolic BP (dBP) >120mmHg, new proteinuria, or new hyperuricaemia). This definition, although 
differing from many international definitions (14) reflects both the variable and multisystem nature 
of pre-eclampsia at presentation and the spectrum of women seen in clinical practice (15). Women 
were excluded if either admitted in spontaneous labour or having achieved any component of the 
maternal outcome prior to either fulfilling eligibility criteria or collection of predictor data. 
The candidate maternal and fetal predictor variables chosen were those that were predictive, 
available, measurable, frequent, and reliable  (Table 1) (20). Symptoms, although difficult to quantify, 
were included for face validity due to their use to classify severe disease (12;14), and potential 
predictive performance in pre-eclampsia (16). While some of the candidate predictors were 
associated with components of the outcome (e.g. the predictor of creatinine and the outcome 
component of renal insufficiency or failure) they were retained for consideration in the model 
because we were interested in predicting the development of adverse events in the future based on 
information available at the time of admission. As our study criteria specifically excluded women who 
had achieved any component of the outcome, all women included in the modelling had the potential 
to remain free of adverse outcomes. 
The components of the combined adverse maternal outcome (Table 3) were: maternal mortality or 
one/more serious central nervous system, cardiorespiratory, hepatic, renal, or haematological 
morbidities. This outcome was developed by iterative Delphi consensus (17;18). A single case of 
Bell’s palsy and two cases of severe ascites were included as the onset and resolution were 
temporally related to the clinical course of the pre-eclampsia.  
Data quality and missing data 
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Customised case report forms and database were utilised by all participating sites. Data were 
collected from the patient medical record(s) and predictor variables were collected within 48 hours 
of eligibility. If absent, the ‘last observation carried forward’ method was used by which any 
preceding observation performed within two weeks of admission was considered current unless 
replaced by a more recent value. While not universally supported (19), this is consistent with clinical 
practice as clinicians do not re-evaluate what they believe has not changed, and is conservative in 
underestimating the effect of any given variable in modelling. For example, 24 hour urine 
proteinuria of 0.6g/d measured 4 days previously could be carried forward to the day of delivery for 
the purpose of the analyses. 
Lead-time bias: We selected either the date/time of admission with pre-eclampsia or the post-
admission development of pre-eclampsia (which ever was later) to standardise for the level of 
clinical concern justifying admission and the concurrent presence of pre-eclampsia. 
Missing values and misclassification: We undertook abstractor training, checked the data collection 
methods, monitored data logic, and performed random re-abstraction of charts (randomly in 102 
(5%) cases and for all adverse maternal or perinatal outcomes were suspected or confirmed). Cases 
of uncertainty (n=13 [1.0%]) were resolved by iterative discussion between PvD, LAM, BP, and the 
relevant site investigator. 
One highly informative variable, oxygen saturation by pulse oximetry (SpO2), was prone to missing 
data before all participating centres achieved regular pulse oximetry. Missing pulse oximetry data 
points were assigned a value, 97%, to lie within the normal range (95-100%), assuming that non-use 
of oximetry was associated with better clinical state, and biasing analyses to underestimate the 
impact of falling SpO2 to identify increasing maternal risk (20). 
Study size 
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In response to a falling incidence of adverse outcomes observed in all centres, and previously 
reported in one site (11), an early decision was made to assess the model iteratively once 200 women 
were entered into the database, and monthly thereafter, so that non-informative variables (p>0.2) 
could be abandoned. Study size was based on the following calculation: 
N = (n x15)/I = 1731women (21-23) 
where N is the sample size, n = number of informative, non-convergent variables to be considered 
in the model (= 15), and I = incidence of the combined adverse outcome (0.13 at any time after 
eligibility).  
Quantitative variables 
For lactate dehydrogenase (LDH), values were corrected to the midpoint of the relevant laboratory’s 
normal range to standardise across sites. For women who developed de novo postpartum pre-
eclampsia, gestational age was defined as the gestational age at delivery. 
Statistical methods 
Only candidate predictor variables available for ≥80% of the women were included in modelling, as, 
routine use is a prerequisite for day-to-day clinical utility. Consequently, we considered 54 
independent variables collected over the first 48 hours to predict the combined adverse maternal 
outcome occurring within the first 48 hours after eligibility (Table 1). The ‘worst value’ (e.g., highest 
sBP or lowest platelet count) measured prior to outcome occurrence or completion of the 48 hour 
time period, whichever was first, was used. A 48 hour time period was chosen because it would 
improve perinatal outcomes by giving time for steroid administration remote from term and it 
would inform decisions about the place of delivery/in utero transfer from level 1 and 2 units. 
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The relationship between each predictor variable and the combined adverse maternal outcome was 
assessed by univariable logistic regression. Continuous variables were modelled using quadratic 
terms, and categorised based on risk thresholds to evaluate the potential for non-linearity. Variables 
associated with the outcome (p<0.1) were included in the initial multivariable regression model 
along with variables deemed important, a priori, on clinical grounds. To avoid colinearity, the 
correlation between variables was assessed and the more clinically relevant variable of a pair of 
highly correlated variables included. Clinical expectations regarding possible interactions were 
specifically examined. 
Stepwise backward elimination was used to build the parsimonious final model. The AUC of the 
receiver-operating characteristics curve (ROC) was calculated using standard methods (24). The final 
model was internally validated using Efron’s enhanced bootstrap method (details available 
[www.piers.cfri.ca]) (22;25;26). Such a bootstrap validation is recommended over alternative 
validation approaches (e.g., splitting data into training and test datasets) because it maximises 
statistical efficiency and directly validates the final model (22). 
Performance was assessed using calibration ability, stratification capacity, and classification accuracy 
(27). 
Model performance in related clinical contexts 
In addition, we prospectively assessed the predictive ability of fullPIERS in a broader range of 
women with pregnancy hypertension. First, women admitted with pre-eclampsia to five level I/II 
obstetric centres in British Columbia (n=4) and Western Australia (n=1). Second, women admitted 
to BC Women’s with either pre-existing or gestational hypertension (17). Third, women with pre-
eclampsia admitted to three academic centres in low and middle income countries (Fiji, South 
Africa, and Uganda).  
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 RESULTS 
From 1 September 2003 - 31 January 2010, data for 2023 women (2221 fetuses) were entered into 
the fullPIERS database from eight international sites (Table 2). There were 261 (12.9 %) combined 
adverse maternal outcomes at any time following eligibility. Compared with the women who did not 
develop adverse outcomes, the women who developed adverse outcomes were of lower gestational 
age at eligibility, and less likely to be either parous, to smoke during the pregnancy, or to be eligible 
on the basis of hyperuricaemia. They were more likely to develop HELLP syndrome, and to receive 
both antihypertensives and/or antenatal corticosteroids (for either fetal lung maturation or HELLP). 
Maternal blood pressure indices, dipstick proteinuria, and AST were higher in women who 
developed adverse outcomes, while platelet counts were lower. The eligibility-to-delivery interval did 
not vary between groups, except among women eligible at <34wk. Such women who developed 
outcomes had briefer eligibility-to-delivery intervals. Women who developed adverse outcomes were 
more likely to receive MgSO4 during their clinical course (62% vs 30%) and to deliver babies earlier 
and of lower birth weight. Perinatal and infant mortality did not differ significantly between groups.  
The median eligibility-to-outcome interval was 4 days (Table 3). These adverse outcomes occurred 
antenatally in 6.0% of women, intrapartum in 3.4%, and postnatally in 3.5%. The most common 
outcomes reached were pulmonary oedema (63 (3%)) or blood product transfusion (85 (4%)). 
Having excluded some historically important variables after univariable modelling, we modelled 
using variables with possible explanatory power (Table 4; full list of tested variables and univariable 
relations with the combined adverse outcome available [www.piers.cfri.ca]). 
Developed with data from 1935 women during the first 48 hours after eligibility, fullPIERS, predicts 
adverse maternal outcomes within 48 hours of eligibility (AUC ROC 0.88 [95% CI 0.84, 0.92]) 
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(Figure 1). The final fullPIERS equation was: logit(pi) = 2.68 + -5.41 x 10-2 (gestational age 
(eligibility)) + 1.23 (chest pain/dyspnoea) + -2.71 x 10-2 (creatinine) + 2.07 x 10-1 (platelets) + 4.00 
x 10-5 (platelets2) + 1.01 x 10-2 (AST) + -3.05 x 10-6 (AST2) + 2.50 x 10-4 (creatinine x platelet) + -
6.99 x 10-5 (platelet x AST) + -2.56 x 10-3 (platelet x SpO2). On-line fullPIERS propability 
calculator available (www.piers.cfri.ca). After 200 cycles of bootstrapping the average optimism was 
0.02 [95% CI -0.03, 0.06,] suggesting minimal overfitting. 
fullPIERS successfully stratified the population into clinically relevant risk categories (Table 5), with 
a large percentage (65%) of women classified into a low risk group (predicted probability of <0.025), 
and 4% of women into the highest risk group (predicted probability ≥0.30). The majority (60%) of 
women with a predicted probability ≥0.30 had an adverse outcome. Conversely, the adverse 
outcome only occurred in 1.1% ((11+3)/(671+586)) of women with a predicted probability of 
<0.025, and in only 0.4% of women with a predicted probability <0.01 (negative predictive value:, 
99.6%).  
The classification accuracy of fullPIERS was good. For example, using a predicted probability of 
0.05 as a threshold, fullPIERS identified >75% of women who subsequently had events as being 
‘high risk,’ while only 16% of the population was incorrectly identified as being ‘high risk.’ In 
practice, the predicted probability would best be used as a continuous value, “probability of an 
adverse outcome,” to customise management.  
 fullPIERS also performed well predicting adverse maternal outcome from 2 to 7 days following 
eligibility (i.e., AUC ROC >0.7; Figure 2).  
These AUC and risk stratification findings were replicated for women admitted with pre-eclampsia 
prior to 34+0 weeks (AUC ROC 0.85 [95% CI 0.79, 0.92]) and for primigravid women admitted with 
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pre-eclampsia defined solely as proteinuric gestational hypertension (AUC ROC 0.87 [95% CI 0.82, 
0.93]) (tables available [www.piers.cfri.ca]). 
Preliminary assessments of fullPIERS in a broader range of women with pregnancy hypertension 
confirmed its performance (i.e., AUC ROC >0.7). The AUC ROC for fullPIERS was 0.77 [95% CI 
0.45, 1.00], 0.85 [95% CI 0.65, 1.00], and 0.80 [95% CI 0.66, 0.94] for women admitted to level I/II 
centres with pre-eclampsia (n=6 outcomes/139 women), one tertiary centre (level III) with a non-
pre-eclampsia HDP (n=4/224), and LMIC centres with pre-eclampsia (n=17/145), respectively.  
 
DISCUSSION 
Key results 
We carried out a prospective, international study to develop and validate a maternal outcome 
prediction model for women admitted to tertiary units with pre-eclampsia. Among women admitted 
to hospital with pre-eclampsia, fullPIERS predicted adverse maternal outcomes occurring within the 
first 48 hour following eligibility [AUC ROC 0.88]. The model included the following predictors: 
gestational age at eligibility, chest pain/dyspnoea, SpO2, platelet count, serum creatinine, and AST. 
PIERS modelling identified SpO2, a clinical variable that has not been included traditionally in lists 
of adverse features. All components of the model fulfilled the requirement for clinical face validity, 
in view of the particular risks of pre-eclampsia (5), especially remote from term (1). fullPIERS 
attained similar stratification capacity, calibration ability, and classification accuracy as established 
cardiovascular, adult critical care, and neonatal critical care scores (28-30). fullPIERS should assist 
decisions around delivery, especially at gestational ages when expectant management has important 
perinatal advantages (1). 
Limitations 
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There are several limitations to this study. 
First, to attain generalizability, our population included women who fulfilled a broad definition of 
pre-eclampsia, including women without significant proteinuria. Restricting the analysis to the 
tightest possible research definition (primigravid women with proteinuric hypertension) did not 
meaningfully change the AUC ROC.  
Second, while components of our combined adverse maternal outcome are not of equal value, all 
components were assessed and validated by iterative Delphi consensus (17;18) and are 
independently worthy of avoidance. 
Third, the study was performed solely in high income country tertiary obstetric units and in women 
fulfilling our research definition of pre-eclampsia. We have begun to address these limitations 
through initial assessments of the predictive ability of fullPIERS across the HDP spectrum and are 
developing and validating a specific, symptom- and sign-based, version of PIERS (miniPIERS) for 
use in rural and remote settings in high, middle, and low income countries..  
A fourth limitation was the relatively small sample size, especially when considering the low rate of 
adverse maternal outcomes. This may be particularly important with uncommon outcomes such as 
eclampsia, as headache and/or visual symptoms did not contribute independently to fullPIERS. 
Therefore, our bootstrap validation was only able to confirm the predictive ability of fullPIERS for 
the occurrence of the combined maternal outcome. Since internal validation methods such as the 
bootstrap have limitations (31), we have commenced a process of external validation of fullPIERS 
through new data sets. 
The fifth limitation is that fullPIERS is limited to maternal surveillance and does not address the 
acknowledged excess perinatal risks associated with pre-eclampsia (1).  
Interpretation 
15 
fullPIERS accurately predicted adverse maternal outcomes for up to 48 hours, a clinically useful time 
period that permits steroid administration, transfer, or induction. Also, fullPIERS maintained good 
performance (AUC ROC >0.8), beyond 3 days post-eligibility, and maintained reasonable 
performance (AUC ROC >0.7) up to 7 days post-eligibility. Remote from term, measurable perinatal 
gains accrue at weekly intervals (32). However, like Ganzevoort et al (10), we were unable to predict 
adverse maternal outcomes at any time following admission to hospital with pre-eclampsia. This was 
anticipated, as deteriorating maternal and/or fetal status directs clinical decision making, especially 
remote from term. 
In the PIERS cohort, gestational age on admission for pre-eclampsia was significantly lower, and 
independently predictive, in women destined to develop complications. Disease onset <32 weeks is 
associated with a 20-fold increase in maternal mortality risk (1).  
Many traditional clinical variables of importance were not included in the final model either because 
they were collected in <80% of cases (e.g., 24 hour urine), they lacked univariable association with 
the combined adverse outcome (9), or they were displaced within the multivariable modelling (e.g., 
blood pressure, ‘heavy’ proteinuria, uric acid, ALT, and LDH) by variables with greater independent 
explanatory power. Our findings support the view that once significant proteinuria has been 
identified, serum creatinine can be used for monitoring renal function and risk in women with pre-
eclampsia (33). 
For face validity, we did examine whether or not blood pressure could be forced into fullPIERS. 
Blood pressure did not independently predict adverse maternal outcomes in the multivariable model, 
perhaps as it is the sole element of the maternal syndrome amenable to intervention. Effective 
antihypertensive agents exist for severe and non-severe pregnancy hypertension (1). During the first 
48 hours after eligibility, women who proceeded to develop adverse outcomes had blood pressure 
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indices 3-10mmHg higher than those women with uncomplicated courses. We do not advocate that 
blood pressure measurement in women with suspected or confirmed pre-eclampsia be abandoned. 
Severe systolic (≥160 mmHg) and diastolic hypertension (≥ 110mmHg) convey significant maternal 
risks and should be brought into the non-severe or normotensive range  (1).  
Our results suggest that only one of AST or ALT need to be measured, and that the measurement of 
LDH is redundant in these women. Other tests that could reasonably be abandoned in light of these 
data are urea and routine coagulation studies. 
Why were 24 hour collections performed in fewer than 50% of these women? Pragmatically, we 
believe that clinicians faced with a hypertensive woman with proteinuria on dipstick analysis at term 
will decide to advise delivery rather than accept the delay inherent in a 24 hour collection; a decision 
supported by both the HYPITAT trial (7), and the inaccuracy of 24 hour urine collections for 
proteinuria estimation in pregnancy (33). We suggest that dipstick proteinuria, despite its inherent 
flaws, be used to screen and identify women at risk (1;33). 
The low rate of MgSO4 administration to women who developed adverse outcomes (62%) in these 
academic tertiary centres was surprising; these women all developed significant personal 
complications of pre-eclampsia. While the results of the randomised controlled trials of MgSO4 as 
eclampsia prophylaxis are compelling (34), for women with ‘mild’ pre-eclampsia there remains 
apparent uncertainty about when, and with whom, to start MgSO4 (12). 
Generalisability 
How do we suggest that these findings be used to direct care?  
First, we believe that these data will help clinicians gain a fuller sense of disease evolution. This may 
be what underlay the reduced incidence of adverse maternal outcomes associated with the single site 
introduction of the PIERS assessment and surveillance guidelines (11). 
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Second, we propose that gestational age, maternal symptoms, pulse oximetry, serum creatinine, 
platelet count, and AST be used to stratify maternal risk during the assessment and surveillance of 
women admitted with pre-eclampsia using the fullPIERS equation (available on-line at 
www.piers.cfri.ca). The derived fullPIERS probability has similar performance characteristics as 
established cardiovascular and critical care models. (28-30). 
Third, it appears reasonable to abandon redundant tests. For example, the testing of AST, ALT, and 
LDH might be replaced by AST alone without losing important information and with reduced 
laboratory costs. 
An important impact of fullPIERS may be to identify women at lowest risk of adverse outcomes, 
who can be offered expectant management either remote from term for perinatal benefit  or at or 
near term during induction of labour (7). 
By grouping women according to the risk of adverse maternal outcomes, fullPIERS should also 
contribute to our understanding of the pathophysiology of pre-eclampsia. Analogous to the use of 
POP-Q in pelvic floor prolapse (35), fullPIERS may, over time, aid in describing the heterogeneous 
populations in the pre-eclampsia literature, and enhance the development of new treatments and 
interventions. 
Although the model-making process is not finished (36), we hope that the planned external 
validation (through prospective data collection and using extant international databases) and 
implementation of fullPIERS will help to reduce the risk of the life-ending, life-altering (e.g., stroke), 
and life-threatening (e.g., eclampsia) complications that make pre-eclampsia so important. 
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Table 1 Variables considered in the PIERS modelling 
Variable    
Demographics  Past obstetric history  
Maternal age at EDD (yr)  Gestational hypertension (y/n)  
Number of fetuses  Gestational proteinuria (y/n)  
Gestational age at onset (wk)  GDM (prior preg) (y/n)  
Gestational age at delivery (wk)  GDM (this preg) (y/n)  
Weight – on admission (kg)    
Body mass index (kg/m2)  Past medical history  
Gravidity (n)  Hypertension (y/n)  
Parity (n)  Renal disease (y/n)  
Smoking in this pregnancy (y/n)  Diabetes mellitus (y/n)  
Symptoms  Cardiorespiratory signs  
Severe nausea and vomiting (y/n)  dBP on eligibility (mmHg)  
Frontal headache (y/n)  sBP on eligibility (mmHg)  
Visual disturbance (y/n)  MAP on eligibility (mmHg)  
RUQ/epigastric pain (y/n)  SpO2 (%)/SpO2 (filled) * (%)  
Chest pain/dyspnoea (y/n)    
≥1 symptom (y/n)    
Haematological tests  Renal signs and tests  
Total leukocyte count (x 109/L)  Dipstick (categorical) †   
Platelet count (x 109/L)  Dipstick (continuous) ‡  
MPV (fL)  24h urine protein (g/d)  
27 
MPV/plt ratio  Pr:Cr ratio (mg/mM)  
INR  Creatinine (mmol/L)  
APTT (sec)  Uric acid (mmol/L)  
Fibrinogen (μmol/L)    
Hepatic tests  Fetal assessment tests  
ST (U/L)  FHR (normal/suspicious/pathological) **  
ALT (U/L)  EFW (%ile category) ¶  
LDH as a ratio of the local normal range 
midpoint (U/L)  
AC (%ile category) ¶  
Bilirubin (μmol/L)   UA EDF 
Albumin (g/L)    
Random glucose (mmol/L)    
 
* missing data filled assuming 97% (described in the Methods); † classified as 0, trace, 1+, 2+, 3+, 
4+; ‡ classified as 0, 0.5, 1, 2, 3, 4; ¶ classified as <1.0%, 1.0-2.4%, 2.5-4.9%, 5.0-9.9%, 10.0-49.9%, 
50.0-89.9%, 90.0-94.9%, 95.0-97.4%, 97.5-98.9%, ≥99.0% using BC Women’s Hospital published 
data (37); ** using Royal College of Obstetricians and Gynaecologists definitions 
(http://www.rcog.org.uk/resources/public/pdf/efm_guideline_final_2may2001.pdf). 
AC abdominal circumference; AFI amniotic fluid index; ALT alanine transaminase; APTT activated 
partial thromboplastin time; AST aspartate transamninase; BPP biophysical profile; DAP deepest 
amniotic fluid pocket; dBP diastolic blood pressure; EDD expected date of delivery; EFW estimated 
fetal weight (Hadlock (38)); FHR fetal heart rate; GDM gestational diabetes mellitus; INR 
international normalised ratio; LDH lactate dehydrongenase; MAP mean arterial pressure; MPV 
28 
mean platelet volume; preg pregnancy; RUQ rught upper quadrant; SpO2 oxygen saturation (pulse 
oximetry); sBP systolic blood pressure; UA EDF umbilical artery Doppler end diastolic flow 
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Table 2 Characteristics of women in the PIERS study (median [interquartile range] and number (%)) 
Characteristic  Women with 
adverse 
outcomes 
(N=261 ) 
Women without 
adverse 
outcomes 
(N=1762 ) 
p value 
 
Demographics (within 48h of eligibility)      
Maternal age at EDD (years)  31 [27, 35] 31 [27, 36] 0.68 
Gestational age at eligibility (weeks)  33.9 [30.0, 36.6] 36.3 [33.4, 38.3] 8.2E-20 
Gestational age at eligibility <34 weeks  133 (51.0%) 503 (28.5%) 3.3E-12 
Multiple pregnancy  36 (13.8%) 156 (8.9%) 0.02 
Parity ≥ 1  72 (27.6%) 509 (28.9%) 0.71 
Smoking in this pregnancy  26 (10.0%) 223 (12.7%) 0.26 
Pre-eclampsia description      
   Hypertension and proteinuria  178 (68.2%) 1164 (66.1%) 0.53 
   Hypertension and hyperuricaemia  21 (8.0%) 303 (17.2%) 8.9E-05 
   HELLP without hypertension or proteinuria  23 (8.8%) 29 (1.6%) 8.0E-08 
   Superimposed pre-eclampsia  39 (14.9%) 266 (15.1%) 1.0 
Clinical (within 48h of eligibility)     
Peak blood pressure (mmHg)     
   Mean arterial pressure  123 [116, 133] 120 [113, 129] 5.2E-05 
   Systolic BP  170 [155, 181] 160 [150, 175] 1.7E-06 
   Diastolic BP  104 [98, 112] 101 [97, 110] 0.02 
Worst dipstick proteinuria (+) 3 [1, 4] 2 [trace, 3] 6.7E-11 
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Lowest platelets (x 109/L) 170 [121, 230] 194 [153, 243] 2.8E-06 
Highest aspartate transaminase (U/L) 31 [22, 51] 26 [20, 36] 4.5E-07 
Interventions     
Corticosteroid administration  114 (43.7%) 436 (24.7%) 5.8E-10 
Antihypertensive medications administered  214 (82.0%) 1167 (66.2%) 6.9E-08 
MgSO4 administered  161 (61.7%) 529 (30.0%) 4.7E-22 
Pregnancy outcomes     
Admission-to-delivery interval (all cases) (d)  2 [1, 6] 2 [1, 5] 0.14 
Admission-to-delivery interval (<34+0 wks) 
(d)  
4 [1, 9] 5 [2, 16] 0.01 
Gestational age at delivery (wk)  34.7 [30.7, 37.0] 37.0 [34.6, 38.7] 8.2E-20 
Birth weight (g)  1938 [1189, 2750] 2685 [1935, 3300] 4.5E-18 
Birth weight  <3rd percentile*  22 (8.4%) 143 (8.1%) 0.90 
Intrauterine fetal death (≥20+0 wk and/or 
≥500g)  
4 (1.5%) 16 (0.9%) 0.31 
Neonatal death (before 28d)  5 (1.9%) 15 (0.9%) 0.17 
Infant death prior to hospital discharge or 6wk 7 (2.7%) 19 (1.1%) 0.07 
 
dBP diastolic blood pressure; EDD expected date of delivery; HELLP haemolysis, elevated liver 
enzymes, low platelets; sBP systolic blood pressure. * Data from Kramer et al (39).  
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Table 3 Adverse maternal outcomes (definitions available [www.piers.cfri.ca])  
One or more of maternal morbidity or mortality: within 48h within 7d any time 
TOTAL   106 (5.2%) 203 (10.0%) 261 (12.9%) 
Maternal death  0 0 0 
Central nervous system     
Eclampsia (≥1)  6 10 11 
Glasgow coma score <13  1 1 3 
Stroke or reversible ischaemic neurological deficit  0 0 1 
Transient ischaemic attack  0 1 1 
Cortical blindness or retinal detachment  0 0 0 
Posterior reversible encephalopathy  0 0 0 
Cardiorespiratory     
Positive inotropic support  0 0 3 
Infusion of a 3rd parenteral antihypertensive  0 1 3 
Myocardial ischaemia/infarction  1 1 1 
SpO2 <90%  11 30 41 
≥50% FiO2 for >1hr  12 21 32 
Intubation (other than for Caesarean section) 1 4 6 
Pulmonary oedema  22 52 63 
Haematological     
Transfusion of any blood product  28 63 85 
Platelets <50 x 109/L with no transfusion  22 36 40 
Hepatic     
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Dysfunction  9 11 12 
Haematoma/rupture  0 0 0 
Renal     
Acute renal insufficiency (creatinine > 150μmol/L; 
no pre-existing renal disease) (40) 
3 4 6 
Acute renal failure (creatinine>200μmol/L; pre-
existing renal disease) (40) 
4 4 4 
Dialysis  0 0 1 
Placental outcomes     
Placental abruption  15 24 34 
Other adverse events     
Severe ascites  1 2 2 
Bell’s palsy  0 1 1 
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Table 4 Univariable analyses of candidate predictor variables with p<0.1 and collected in >80% of 
cases  
Variable  N (%)  OR [95% CI]  P value  AUC ROC [95% 
CI] 
Demographics          
Maternal age at EDD (yr)  2020 (99.9) 0.99 [0.96, 1.02] 0.57  0.51 [0.46, 0.57]  
Number of fetuses (n)  2020 (99.9) 0.86 [0.43, 1.70] 0.66  0.51 [0.45, 0.57]  
Gravidity (n)  2020 (99.9) 0.894 [0.81, 0.99] 0.03  0.56 [0.50, 0.61]  
Weight at eligibility (kg)  1784 (88.2) 0.99 [0.97, 0.998] 0.03  0.59 [0.53, 0.65]  
BMI (kg/m2)  1647 (81.4) 0.99 [0.95, 1.02] 0.45  0.55 [0.49, 0.61]  
Height (cm)  1763 (87.2) 0.99 [0.97, 1.02] 0.62  0.52 [0.46, 0.58]  
Past medical history          
Hypertension (y/n)  2015 (99.6) 0.57 [0.29, 1.11] 0.10  0.53 [0.48, 0.58]  
Symptoms          
Severe nausea and vomiting 
(y/n)  
2020 (99.9) 2.14 [1.22, 3.73] 0.008  0.54 [0.48, 0.60]  
RUQ/epigastric pain (y/n)  2020 (99.9) 2.92 [1.94, 4.39] 2.7E-07   0.61 [0.55, 0.66]  
Headache (y/n)  2020 (99.9) 1.23 [0.83, 1.83] 0.30  0.53 [0.47, 0.58]  
Visual disturbance (y/n)  2020 (99.9) 0.99 [0.60, 1.63] 0.96  0.50 [0.45, 0.56]  
Chest pain/dyspnoea (y/n)  2020 (99.9) 6.13 [3.56, 10.54] 5.6E-11 0.58 [0.52, 0.66]  
Number of symptoms (n)  2020 (99.9) 1.49 [1.26, 1.76] 3.2E-06 0.62 [0.57, 0.68]  
Cardiovascular signs        
dBP on eligibility (mmHg)  2020 (99.9) 1.04 [1.02, 1.05] 8.6E-05 0.63 [0.57, 0.68]  
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sBP on eligibility mmHg)  2020 (99.9) 1.03 [1.02, 1.04] 1.1E-08 0.65 [0.59, 0.70]  
MAP on eligibility (mmHg)  2019 (99.8) 1.04 [1.03, 1.06] 4.6E-08 0.65 [0. 60, 0.71]  
Respiratory          
SpO2 (filled) (%) * 2020 (99.9) 0.63 [0.58, 0.70] 4.8E-22  0.72 [0.67, 0.78]  
Renal          
Dipstick (continuous) † 1949 (96.3) 1.43 [1.24, 1.66] 1.6E-06 0.65 [0.59, 0.71]  
Creatinine (μmol/L)  2000 (98.9) 1.02 [1.02, 1.03] 4.2E-09 0.63 [0.57, 0.69]  
Uric acid (mmol/L)  2008 (99.3) 1.004 [1.00, 1.01] 1.1E-04 0.59 [0.53, 0.65]  
Haematological          
Platelet count (x 109/L)  2015 (99.6) 0.99 [0.98, 0.99] 4.9E-17 0.69 [0.63, 0.75]  
Mean platelet volume (fL)  1953 (96.5) 1.00 [0.88, 1.13] 0.939  0.51 [0.46, 0.57]  
MPV x 106/platelet count 
ratio  
1952 (96.5) 45.46 [1.63, 1269] 2.9E-25 0.66 [0.59, 0.72]  
International normalised ratio 
(INR)  
1758 (86.9) 2710 [143, 51381] 1.3E-07 0.64 [0.58, 0.70]  
Activated partial 
thromboplastin time (sec)  
1759 (87.0) 1.04 [1.02, 1.07] 1.7E-04 0.64 [0.58, 0.70]  
Hepatic          
Aspartate transaminase (U/L)  1947 (96.2) 1.005 [1.00, 1.01] 1.6E-14 0.73 [0.67, 0.79]  
Alanine transaminase (U/L)  2011 (99.4) 1.005 [1.00, 1.01] 7.9E-16 0.72 [0.66, 0.78]  
Lactate dehydrogenase (U/L)  1623 (80.2) 1.63 [1.43, 1.86] 2.0E-13 0.75 [0.68, 0.81]  
Bilirubin (μmol/L)  1911 (94.5) 1.15 [1.11, 1.18] 8.7E-17  0.67 [0.60, 0.73]  
Albumin (g/L)  1749 (86.5) 0.92 [0.88, 0.96] 7.8E-05 0.62 [0.56, 0.68]  
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Fetal assessment tests          
FHR  1829 (90.4) 2.15 [1.47, 3.14] 6.9E-05 0.58 [0.51, 0.64]  
EFW (%ile category)  1665 (82.3) 0.99 [0.98, 0.99] 5.9E-05 
 
0.61 [0.55, 0.68]  
AC (%ile category)  1665 (82.3) 0.99[0.98, 0.99] 5.8E-05 0.61 [0.55, 0.68]  
 
* missing data filled assuming 97% (described in the Methods); † classified as 0, 0.5, 1, 2, 3, 4. 
%ile percentile; AC abdominal circumference; BMI body mass index; dBP diastolic blood pressure; 
MAP mean arterial pressure; MPV mean platelet volume; RUQ right upper quadrant; SpO2 oxygen 
saturation (pulse oximetry); sBP systolic blood pressure 
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Table 5 Risk stratification table assessing the value of the fullPIERS model in risk prediction 
Predicted 
probability of 
adverse 
maternal 
outcome 
within 48 
hours  
Number of 
women (%) 
Number of 
women with 
outcome (%) 
Number of 
women 
without 
outcome (%)
True 
positive 
rate*  
False 
positive 
rate*  
0.00 – 0.0099 671 (34.7%) 3 (0.4%) 668 (99.6%)   
0.01 – 0.024 586 (30.3%) 11 (1.9%) 575 (98.1%) 0.969 0.636 
0.025 – 0.049  314 (16.2%) 9 (2.9%)  305 (97.1%) 0.857 0.323 
0.050 - 0.099  160 (8.3%) 8 (5.0%)  152 (95.0%) 0.765 0.157 
0.10 - 0.19  98 (5.1%) 14 (14.3%)  84 (85.7%) 0.684  0.073  
0.20 - 0.29  32 (1.65%) 9 (28.13%)  23 (71.88%) 0.541 0.029 
≥0.30  74 (3.82%) 44 (59.46%) 30 (40.54%) 0.449 0.016 
Total  1935  98  1837   
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Sens: 0.755
Spec: 0.869
PV+:  0.236
PV‐:   0.985
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Figure 1 Performance of the fullPIERS model developed with data from first 48h after eligibility. 
Combined adverse maternal outcome predicted within 48h of eligibility using only data collected 
prior to the outcome (an on-line tool to calculate fullPIERS probabilities is available at 
www.piers.cfri.ca). 
AUC ROC area under the curve of the receiver operator characteristic; PV- negative predictive 
value; PV+ positive predictive value; Sens sensitivity; Spec specificity 
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Figure 2 fullPIERS areas under the receiver-operator curves (AUCs; error bars: 95% confidence 
intervals) from 2 – 7 days after PIERS study eligibility.  
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